13G Filing: Viking Global and Editas Medicine, Inc. (EDIT)

As a new 13G filing with the US Securities and Exchange Commission showed, Andreas Halvorsen‘s Viking Global holds a long position in Editas Medicine Inc (NASDAQ:EDIT). The filing revealed that Viking Global holds a passive stake in the company, which contains 2.73 million shares of Editas. The holding amasses 7.5% of the company’s outstanding common stock. Editas Medicine went public and started trading last week.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 2,729,808 0 2,729,808 2,729,808 7.5%
Viking Global Performance 0 753,625 0 753,625 753,625 2.1%
Viking Global Equities 0 256,986 0 256,986 256,986 0.7%
Viking Global Equities II 0 15,072 0 15,072 15,072 0.0%
VGE III Portfolio Ltd. 0 481,567 0 481,567 481,567 1.3%
Viking Long Fund GP 0 266,782 0 266,782 266,782 0.7%
Viking Long Fund Master Ltd. 0 266,782 0 266,782 266,782 0.7%
Viking Global Opportunities GP 0 1,709,401 0 1,709,401 1,709,401 4.7%
Viking Global Opportunities Portfolio GP 0 1,709,401 0 1,709,401 1,709,401 4.7%
Viking Global Opportunities Illiquid Investments Sub-Master 0 1,709,401 0 1,709,401 1,709,401 4.7%
O. Andreas Halvorsen 0 2,729,808 0 2,729,808 2,729,808 7.5%
David C. Ott 0 2,729,808 0 2,729,808 2,729,808 7.5%
Daniel S. Sundheim 0 2,729,808 0 2,729,808 2,729,808 7.5%

Follow Andreas Halvorsen's Viking Global

Page 1 of 20 SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________

Schedule 13G
________________

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934*

Editas Medicine, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

28106W103
(CUSIP Number)

February 8, 2016
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

___________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Editas Medicine Inc.

Page 2 of 20 SEC Filing

Schedule 13G PAGE 2 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Investors LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,729,808
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,729,808
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,729,808
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
7.5%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 3 of 20 SEC Filing

Schedule 13G PAGE 3 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Performance LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
753,625
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
753,625
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
753,625
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
2.1%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 4 of 20 SEC Filing

Schedule 13G PAGE 4 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Equities LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
256,986
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
256,986
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
256,986
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.7%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 5 of 20 SEC Filing

Schedule 13G PAGE 5 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Equities II LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
15,072
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
15,072
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
15,072
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.0%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 6 of 20 SEC Filing

Schedule 13G PAGE 6 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
VGE III Portfolio Ltd.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
481,567
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
481,567
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
481,567
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.3%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
CO
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 7 of 20 SEC Filing

Schedule 13G PAGE 7 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Long Fund GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
266,782
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
266,782
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
266,782
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.7%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 8 of 20 SEC Filing

Schedule 13G PAGE 8 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Long Fund Master Ltd.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
266,782
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
266,782
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
266,782
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.7%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
CO
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 9 of 20 SEC Filing

Schedule 13G PAGE 9 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
1,709,401
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
1,709,401
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,709,401
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
4.7%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 10 of 20 SEC Filing

Schedule 13G PAGE 10 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities Portfolio GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
1,709,401
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
1,709,401
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,709,401
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
4.7%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 11 of 20 SEC Filing

Schedule 13G PAGE 11 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities Illiquid Investments Sub-Master LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
1,709,401
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
1,709,401
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,709,401
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
4.7%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 12 of 20 SEC Filing

Schedule 13G PAGE 12 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
O. Andreas Halvorsen
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Norway
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,729,808
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,729,808
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,729,808
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
7.5%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 13 of 20 SEC Filing

Schedule 13G PAGE 13 of 20

CUSIP No. 28106W103
_____________________________________________________________________________

(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
David C. Ott
_____________________________________________________________________________

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________

(3) SEC USE ONLY
_____________________________________________________________________________

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,729,808
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,729,808
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,729,808
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
7.5%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 14 of 20 SEC Filing

Schedule 13G PAGE 14 of 20

CUSIP No. 28106W103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Daniel S. Sundheim
_____________________________________________________________________________

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________

(3) SEC USE ONLY
_____________________________________________________________________________

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,729,808
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,729,808
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,729,808
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
7.5%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

Follow Editas Medicine Inc.

Page 15 of 20 SEC Filing

Schedule 13G PAGE 15 of 20

CUSIP No. 28106W103

ITEM 1(a). NAME OF ISSUER:
Editas Medicine, Inc.

ITEM 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
300 Third Street, First Floor
Cambridge, Massachusetts 02142

ITEM 2(a). NAME OF PERSON FILING:
Viking Global Investors LP (“VGI”),
Viking Global Performance LLC (“VGP”),
Viking Global Equities LP (“VGE”),
Viking Global Equities II LP (“VGEII”),
VGE III Portfolio Ltd. (“VGEIII”),
Viking Long Fund GP LLC (“VLFGP”),
Viking Long Fund Master Ltd. (“VLFM”),
Viking Global Opportunities GP LLC (“Opportunities GP”),
Viking Global Opportunities Portfolio GP LLC
(“Opportunities Portfolio GP”),
Viking Global Opportunities Illiquid Investments Sub-Master LP
(“Opportunities Fund”),
O. Andreas Halvorsen, David C. Ott and
Daniel S. Sundheim (collectively, the “Reporting Persons”)

ITEM 2(b). ADDRESS OF PRINCIPAL OFFICE OR, IF NONE, RESIDENCE:
The business address of each of the Reporting Persons is
55 Railroad Avenue, Greenwich, Connecticut 06830.

ITEM 2(c). CITIZENSHIP:
VGI, VGE and VGEII are Delaware limited partnerships;
VGEIII and VLFM are Cayman Islands exempted companies;
VGP, VLFGP, Opportunities GP and Opportunities Portfolio GP
are Delaware limited liability companies; and Opportunities Fund
is a Cayman Islands exempted limited partnership.
O. Andreas Halvorsen is a citizen of Norway.
David C. Ott and Daniel S. Sundheim are citizens of
the United States.

ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock (“Common Stock”)

ITEM 2(e). CUSIP NUMBER: 28106W103

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c),
CHECK WHETHER THE PERSON FILING IS A:

(a) [ ] Broker or dealer registered under Section 15 of the
Act

(b) [ ] Bank as defined in Section 3(a)(6) of the Act

(c) [ ] Insurance Company as defined in Section 3(a)(19) of
the Act

(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940

(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940: see Rule 13d-
1(b)(1)(ii)(E)

(f) [ ] Employee Benefit Plan, Pension Fund which is subject
to the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund; see Rule 13d-
1(b)(1)(ii)(F)

Follow Editas Medicine Inc.

Page 16 of 20 SEC Filing

Schedule 13G PAGE 16 of 20

CUSIP No. 28106W103

(g) [ ] Parent Holding Company, in accordance with Rule 13d-
1(b)(ii)(G)

(h) [ ] Savings Associations as defined in Section 3(b) of the
Federal Deposit Insurance Act

(i) [ ] Church Plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the
Investment Company Act of 1940

(j) [ ] A non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J)

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J), please specify
the type of institution:

ITEM 4. OWNERSHIP.

A. VGI
(a) Amount beneficially owned: 2,729,808
(b) Percent of class: 7.5%
The percentages used herein and in this Item 4 are calculated based
upon the Company’s Prospectus on Form 424B1 filed on February 3, 2016,
and press release issued on February 8, 2016, which state that as of
February 8, 2016 there were 36,584,538 shares of Common Stock
outstanding.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,729,808
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,729,808

VGI provides managerial services to VGE, VGEII, VGEIII, VLFM
and Opportunities Fund. VGI has the authority to dispose of and vote
the shares of Common Stock.

Based on Rule 13d-3 of the Securities Exchange Act of 1934,
as amended (the “Act”), VGI may be deemed to beneficially
own the shares of Common Stock directly held by VGE, VGEII,
VGEIII, VLFM and Opportunities Fund. VGI does not directly own
any shares of Common Stock.

Follow Editas Medicine Inc.

Page 17 of 20 SEC Filing

Schedule 13G PAGE 17 of 20

CUSIP No. 28106W103

B. VGP
(a) Amount beneficially owned: 753,625
(b) Percent of class: 2.1%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
753,625
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 753,625

VGP, as the general partner of VGE and VGEII, has the
authority to dispose of and vote the shares of Common Stock
directly owned by VGE and VGEII. VGP serves as investment
manager to VGEIII and has the authority to dispose of and vote
the shares of Common Stock directly owned by VGEIII. VGP does
not directly own any shares of Common Stock.

Based on Rule 13d-3 of the Act, VGP may be deemed to
beneficially own the shares of Common Stock directly held by
VGE, VGEII and VGEIII.

C. VLFGP
(a) Amount beneficially owned: 266,782
(b) Percent of class: 0.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
266,782
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 266,782

VLFGP serves as the investment manager of VLFM and has the
authority to dispose of and vote the shares of Common Stock
directly owned by VLFM. VLFGP does not directly own
any shares of Common Stock.

Based on Rule 13d-3 of the Act, VLFGP may be deemed to
beneficially own the shares of Common Stock directly held by
VLFM.

D. Opportunities GP
(a) Amount beneficially owned: 1,709,401
(b) Percent of class: 4.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
1,709,401
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 1,709,401

Opportunities GP serves as the sole member of Opportunities
Portfolio GP and has the authority to dispose of and vote the
shares of Common Stock controlled by Opportunities Portfolio GP,
which consists of the shares of Common Stock directly held by
Opportunities Fund. Opportunities GP does not directly own
any shares of Common Stock.

Based on Rule 13d-3 of the Act, Opportunities GP may be
deemed to beneficially own the shares of Common Stock
controlled by Opportunities Portfolio GP, which consists of
the shares of Common Stock directly held by Opportunities Fund.

E. Opportunities Portfolio GP
(a) Amount beneficially owned: 1,709,401
(b) Percent of class: 4.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
1,709,401
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 1,709,401

Opportunities Portfolio GP serves as the general partner of
Opportunities Fund and has the authority to dispose of and vote the shares
of Common Stock directly owned by Opportunities Fund. Opportunities
Portfolio GP does not directly own any shares of Common Stock.

Based on Rule 13d-3 of the Act, Opportunities Portfolio GP
may be deemed to beneficially own the shares of Common Stock
directly held by Opportunities Fund.

Follow Editas Medicine Inc.

Page 18 of 20 SEC Filing

Schedule 13G PAGE 18 of 20

CUSIP No. 28106W103

F. VGE
(a) Amount beneficially owned: 256,986
(b) Percent of class: 0.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
256,986
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 256,986

VGE has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its general partner, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGE.

G. VGEII
(a) Amount beneficially owned: 15,072
(b) Percent of class: 0.0%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
15,072
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 15,072

VGEII has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its general partner, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGEII.

H. VGEIII
(a) Amount beneficially owned: 481,567
(b) Percent of class: 1.3%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
481,567
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 481,567

VGEIII has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its investment manager, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGEIII.
Viking Global Equities III Ltd. (a Cayman Islands exempted
company) invests substantially all of its assets through VGEIII.

I. VLFM
(a) Amount beneficially owned: 266,782
(b) Percent of class: 0.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
266,782
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 266,782

VLFM has the authority to dispose of and vote the
shares of Common Stock directly owned by it, which power may
be exercised by its investment manager, VLFGP, and by VGI,
an affiliate of VLFGP, which provides managerial services
to VLFM. Viking Long Fund LP (a Delaware limited partnership)
and Viking Long Fund III Ltd. (a Cayman Islands exempted
company), through its investment in Viking Long Fund Intermediate
LP (a Cayman Islands limited partnership), invest substantially
all of their assets through VLFM.

J. Opportunities Fund
(a) Amount beneficially owned: 1,709,401
(b) Percent of class: 4.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
1,709,401
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 1,709,401

Opportunities Fund has the authority to dispose of and vote the
shares of Common Stock directly owned by it, which power may
be exercised by its general partner, Opportunities Portfolio GP,
and by VGI, an affiliate of Opportunities Portfolio GP, which provides
managerial services to Opportunities Fund. Viking Global Opportunities LP
(a Delaware limited partnership) and Viking Global Opportunities III LP
(a Cayman Islands exempted limited partnership), through its investment
in Viking Global Opportunities Intermediate LP (a Cayman Islands
exempted limited partnership), invest substantially all of their
assets in Viking Global Opportunities Master LP (a Cayman Islands
exempted limited partnership), which in turn invests through
Opportunities Fund.

Follow Editas Medicine Inc.

Page 19 of 20 SEC Filing

Schedule 13G PAGE 19 of 20

CUSIP No. 28106W103

K. O. Andreas Halvorsen, David C. Ott and
Daniel S. Sundheim
(a) Amount beneficially owned: 2,729,808
(b) Percent of class: 7.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,729,808
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,729,808

Messrs. Halvorsen, Ott and Sundheim, as
Executive Committee Members of VGI, VGP, VLFGP and Opportunities GP,
have shared authority to dispose of and vote the shares of
Common Stock beneficially owned by VGI, VGP, VLFGP and Opportunities GP.
None of Messrs. Halvorsen, Ott and Sundheim directly
owns any shares of Common Stock.

Based on Rule 13d-3 of the Act, each may be deemed to beneficially
own the shares of Common Stock directly held by VGE, VGE II,
VGEIII, VLFM and Opportunities Fund.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the
date hereof the Reporting Persons has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following.[]

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Yes, see Item 4.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.

ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))
By signing below each Reporting Person certifies that, to the best
of its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and not held in connection with or as a
participant in any transaction having that purpose or effect.

Follow Editas Medicine Inc.

Page 20 of 20 SEC Filing

Schedule 13G PAGE 20 of 20

CUSIP No. 28106W103

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief,
the undersigned certify that the information set forth in this statement is
true, complete and correct.

DATED: February 9, 2016

/s/ O. ANDREAS HALVORSEN
By: O. Andreas Halvorsen – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD., and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

/s/ DAVID C. OTT
By: David C. Ott – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD., and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

/s/ DANIEL S. SUNDHEIM
By: Daniel S. Sundheim – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD., and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

Follow Editas Medicine Inc.